key: cord-0952101-pxldhmvr
authors: Guisado-Vasco, P.; González-Cortijo, L.; D’Errico, G.; Serrera-Alvarez, A.; Sotres-Fernandez, G.; García-Coca, M.; Fernández-Sousa, J.M.; Luepke-Estefan, X.E.; López-Martín, J.A.; Jimeno, J.M.
title: Plitidepsin for the management of a cancer patient infected with SARS-CoV-2 while receiving chemotherapy
date: 2021-07-07
journal: Ann Oncol
DOI: 10.1016/j.annonc.2021.07.003
sha: 13e4a727c684a0208636e94d3322c7de899e461f
doc_id: 952101
cord_uid: pxldhmvr

Plitidepsin is a cyclic peptide that inhibits the host protein elongation factor alpha 1, thus blocking viral replication. A hospitalized patient with stage IIIB gastric signet ring cell carcinoma and multiple comorbidities developed Coronavirus disease (COVID-19) shortly after receiving his first chemotherapy course. He was treated with plitidepsin on a compassionate use basis. The patient showed a substantial acute reduction in viral load 4 days after initiating plitidepsin treatment and was negative for SARS-CoV-2 by day 14. Therapy was well-tolerated, and no COVID-19-related complications were observed. The patient was discharged 18 days after plitidepsin treatment having received a full second course of chemotherapy, with only a 1-week delay from the planned schedule.

Plitidepsin is a cyclic peptide that inhibits the host protein elongation factor alpha 1, thus blocking viral replication. A hospitalized patient with stage IIIB gastric signet ring cell carcinoma and multiple comorbidities developed Coronavirus disease shortly after receiving his first chemotherapy course. He was treated with plitidepsin on a compassionate use basis. The patient showed a substantial acute reduction in viral load 4 days after initiating plitidepsin treatment and was negative for SARS-CoV-2 by day 14.

Therapy was well-tolerated, and no COVID-19-related complications were observed. The patient was discharged 18 days after plitidepsin treatment having received a full second course of chemotherapy, with only a 1-week delay from the planned schedule. Recently, a study with plitidepsin in adults with SARS-CoV-2 infection and who requiring hospital admission assessed that the discharge rates by days 8 and 15 after the start of plitidepsin were 56.8% and 81.8%, respectively (4). Likewise, a mean -4.2 log 10 reduction in viral load from baseline was attained by day 15.

The antiviral mechanism of action of plitidepsin is mediated through inhibition of the host protein elongation factor alpha 1 (EF1A) (5) . Notably, the nucleocapsid protein of SARS-CoV-2 has been showwn to interact directly with EF1A and is essential for viral replication as demonstrated by a significant reduction in viral replication capability following EF1A knockdown. 

In this report, we present our experience using a potential antiviral, plitidepsin, as 

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study

Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China

Utilization of COVID-19 treatments and clinical outcomes among patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study

Plitidepsin has a positive therapeutic index in adult patients with COVID-19 requiring hospitalization

Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A

Acknowledgements. We thank the patient, and his relatives, for his participation in this study, Lorena Martin Peña and Margarita Remirez de Esparza Otero, Ph.D, for providing technical support, and Timothy D. Silverstein, Ph.D. for writing and editorial assistance.